Advertisement

Journal of Neurology

, Volume 255, Supplement 6, pp 28–35 | Cite as

Monoclonal antibodies in the therapy of multiple sclerosis

An overview
  • P. S. RommerEmail author
  • O. Stüve
  • R. Goertsches
  • E. Mix
  • U. K. Zettl
Article

Abstract

With the generation of monoclonal antibodies (mAbs), a new therapeutical concept has gained importance. MAbs aim against selective antigens and so have changed our treatment strategies from non-specific to specific. Four therapeuticals have gained importance in the therapy of multiple sclerosis (MS): One has already been approved for therapy (natalizumab), whereas the other three are either in clinical trials or are about to enter phase III studies. Currently, two phase III studies that evaluate the efficacy of alemtuzumab have begun with recruitment (MS CARE I and II). Another mAb (daclizumab) under study is directed to the interleukin-2α chain (CD25). Results of clinical trials are promising by reporting reduction of relapses and progression in relapsing remitting and secondary progressive MS accompanied by reduction of new lesions in magnetic resonance imaging. A multicenter randomized controlled trial of daclizumab in MS is going to be initiated. Trials with a humanised antibody directed against the cell surface molecule CD20 are under development. Although the future will emphasise this trend to mAbs, the risks should not be ignored as has been shown in recent news. Still, mAbs have the possibility to revolutionise therapeutical concepts in the treatment of immune-mediated diseases, and will therefore be a useful addition to current therapeutic concepts.

Key words

multiple sclerosis natalizumab alemtuzumab daclizumab rituximab 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aksamit AJ (2006) Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist 12:293–298PubMedCrossRefGoogle Scholar
  2. 2.
    Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395–400PubMedCrossRefGoogle Scholar
  3. 3.
    Berger JR (2007) Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep 7:461–469PubMedCrossRefGoogle Scholar
  4. 4.
    Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103:5941–5946PubMedCrossRefGoogle Scholar
  5. 5.
    Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101:8705–8708PubMedCrossRefGoogle Scholar
  6. 6.
    Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME (2008) The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 30:90–98PubMedCrossRefGoogle Scholar
  7. 7.
    Buttmann M, Rieckmann P (2008) Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 8:433–455PubMedCrossRefGoogle Scholar
  8. 8.
    Calabrese LH, Molloy ES, Huang D, Ransohoff RM (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 56:2116–2128PubMedCrossRefGoogle Scholar
  9. 9.
    Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O’Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69:1391–1403PubMedCrossRefGoogle Scholar
  10. 10.
    Champlin RE (1988) Treating multiple sclerosis with monoclonal antibodies: the cons. Neurology 38(Suppl 2):47–49PubMedGoogle Scholar
  11. 11.
    Cobbold SP, Hale G, Clarke MR, Waldmann H (1990) Purging in auto and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms. Prog Clin Biol Res 333:139–151PubMedGoogle Scholar
  12. 12.
    Confavreux C, Vukusic S (2004) Nonspecific immunosuppressants in the treatment of multiple sclerosis. Clin Neurol Neurosurg 106:263–269PubMedCrossRefGoogle Scholar
  13. 13.
    Coles A, Deans J, Compston A (2004) Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 106:270–274PubMedCrossRefGoogle Scholar
  14. 14.
    CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 359(17):1786–801Google Scholar
  15. 15.
    Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98–108PubMedCrossRefGoogle Scholar
  16. 16.
    Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296–304PubMedCrossRefGoogle Scholar
  17. 17.
    Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691–1695PubMedCrossRefGoogle Scholar
  18. 18.
    Cree B (2006) Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12:171–178PubMedCrossRefGoogle Scholar
  19. 19.
    Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272PubMedGoogle Scholar
  20. 20.
    Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180:63–70PubMedCrossRefGoogle Scholar
  21. 21.
    Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP (1992) Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol 87:105–110PubMedCrossRefGoogle Scholar
  22. 22.
    EMEA pressoffice. Hepatotoxicity London 20 March 2008, www.emea.europa.eu/pressoffice/chmp.htmGoogle Scholar
  23. 23.
    Engelhardt B, Kappos L (2008) Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 5:16–22PubMedCrossRefGoogle Scholar
  24. 24.
    Fanale MA, Younes A (2007) Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Drugs 67:333–350PubMedCrossRefGoogle Scholar
  25. 25.
    Flynn JM, Byrd JC (2000) Campath-1H monoclonal antibody therapy. Curr Opin Oncol 12:574–581PubMedCrossRefGoogle Scholar
  26. 26.
    Freim Wahl SG, Folvik MR, Torp SH (2007) Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 26:68–73PubMedGoogle Scholar
  27. 27.
    Garvey B (2008) Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 141:149–169PubMedCrossRefGoogle Scholar
  28. 28.
    Gold R, Jawad A, Miller DH, Henderson DC, Fassas A, Fierz W, Hartung HP (2007) Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 187:156–158PubMedCrossRefGoogle Scholar
  29. 29.
    Greenlee JE (2006) Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications. Int MS J 13:100–107PubMedGoogle Scholar
  30. 30.
    Grillo-López AJ (2000) Rituximab: an insider’s historical perspective. Semin Oncol 27(Suppl 12):9–16PubMedGoogle Scholar
  31. 31.
    Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H (1988) Remission induction in non-Hodgkin Lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 17:1394–1399CrossRefGoogle Scholar
  32. 32.
    Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688PubMedCrossRefGoogle Scholar
  33. 33.
    Hawker K (2008) B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol (Suppl 1):S19–S25Google Scholar
  34. 34.
    Hirst CL, Pace A, Pickersgill TP, Jones R, McLean BN, Zajicek JP, Scolding NJ, Robertson NP (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 255:231–238PubMedCrossRefGoogle Scholar
  35. 35.
    http://clinicaltrial.govGoogle Scholar
  36. 36.
    http://www.emea.europa.eu/humandocs/PDFs/EPAR/tysabri/H-603-Annex-en.pdfGoogle Scholar
  37. 37.
    http://www.fda.gov/cder/drug/infopage/natalizumab/default.htmGoogle Scholar
  38. 38.
    Hünig T (2007) Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 95:111–148PubMedCrossRefGoogle Scholar
  39. 39.
    Johnson KP (2007) Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 13:182–187PubMedCrossRefGoogle Scholar
  40. 40.
    Jones JL, Coles AJ (2008) Campath-1H treatment of multiple sclerosis. Neurodegener Dis 5:27–31PubMedCrossRefGoogle Scholar
  41. 41.
    Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O’Connor PW, King J, Radue EW, Yousry T, Major EO, Clifford DB (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431–441PubMedCrossRefGoogle Scholar
  42. 42.
    Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369–374PubMedCrossRefGoogle Scholar
  43. 43.
    Koch M, Niemeyer G, Patel I, Light S, Nashan B (2002) Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 73:1640–1646PubMedCrossRefGoogle Scholar
  44. 44.
    Kovarik JM, Burtin P (2003) Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin Emerg Drugs 8:47–62PubMedCrossRefGoogle Scholar
  45. 45.
    Kümpfel T, Hohlfeld R (2005) Multiple sclerosis: Between wish and reality. MMW Fortschrit Med 147 Spec No 2:83–85Google Scholar
  46. 46.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375–381PubMedCrossRefGoogle Scholar
  47. 47.
    Linker RA, Kieseier BC (2008) Innovative monoclonal antibody therapies in multiple sclerosis, Ther Adv Neurol Dis 1:33–42CrossRefGoogle Scholar
  48. 48.
    Lutterotti A, Martin R (2008) Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 7:538–547PubMedCrossRefGoogle Scholar
  49. 49.
    Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMedGoogle Scholar
  50. 50.
    Martin R (2008) Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener Dis 5:23–26PubMedCrossRefGoogle Scholar
  51. 51.
    Mechetner E (2007) Development and characterization of mouse hybridomas. Methods Mol Biol 378:1–13PubMedCrossRefGoogle Scholar
  52. 52.
    Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW; International Natalizumab Multiple Sclerosis Trial Group (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23PubMedCrossRefGoogle Scholar
  53. 53.
    Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62:258–264PubMedCrossRefGoogle Scholar
  54. 54.
    Montalban X, Wynn D, Kaufman M, Wang M, Fong A (2007) Preliminary CHOICE results: a phase 2, randomised, double-blind, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. Mult Scler 13(Suppl 2):A18Google Scholar
  55. 55.
    Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119:225–237PubMedCrossRefGoogle Scholar
  56. 56.
    Moreau T, Coles A, Wing M, Thorpe J, Miller D, Moseley I, Isaac J, Hale G, Clayton D, Scolding N, Waldmann H, Compston A (1996) Campath-1H in Multiple Sclerosis. Mult Scler 1:357–365PubMedGoogle Scholar
  57. 57.
    Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344:486Google Scholar
  58. 58.
    Mullen JT, Vartanian TK, Atkins MB (2008) Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358:647–648PubMedCrossRefGoogle Scholar
  59. 59.
    Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2006) Escalating immunomodulatory therapy of multiple sclerosis. Nervenarzt 77:1506–1518Google Scholar
  60. 60.
    O’Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA (2004) Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62:2038–2043PubMedGoogle Scholar
  61. 61.
    Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, Compston DA, Miller DH (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53:751–757PubMedGoogle Scholar
  62. 62.
    Pelosini M, Focosi D, Rita F, Galimberti S, Caracciolo F, Benedetti E, Papineschi F, Petrini M (2008) Progressive multifocal leukoenecephalopahty: report of three cases in HIV-negative haematological patients and review of literature. Ann Hematol 87:405–412PubMedCrossRefGoogle Scholar
  63. 63.
    Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910PubMedCrossRefGoogle Scholar
  64. 64.
    Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S (2000) Daclizumab, a humanized antiinterleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95:83–89PubMedGoogle Scholar
  65. 65.
    Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64:1336–1342PubMedGoogle Scholar
  66. 66.
    Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG (2007) Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 69:785–789PubMedCrossRefGoogle Scholar
  67. 67.
    Rose JW, Watt HE, White AT, Carlson NG (2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56:864–867PubMedCrossRefGoogle Scholar
  68. 68.
    Rudick RA, Sandrock A (2004) Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 4:571–580PubMedCrossRefGoogle Scholar
  69. 69.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923PubMedCrossRefGoogle Scholar
  70. 70.
    Sathasivam S (2008) Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 4:317–327PubMedCrossRefGoogle Scholar
  71. 71.
    Schuna AA (2007) Rituximab for the treatment of rheumatoid arthritis. Pharmacotherapy 27:1702–1710PubMedCrossRefGoogle Scholar
  72. 72.
    Sorensen PS (2005) Multiple sclerosis: pathophysiology revisited. Lancet Neurol 4:9–10PubMedCrossRefGoogle Scholar
  73. 73.
    Sponzilli EE, Smith JK, Malamud N, McCulloch JR (1975) Progressive multifocal leukoencephalopathy: a complication of immunosuppressive treatment. Neurology 25:664–668PubMedGoogle Scholar
  74. 74.
    Stüve O (2008) The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci 274(1–2):39–41PubMedCrossRefGoogle Scholar
  75. 75.
    Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JWC, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B (2007) Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy. Possible interventions. Arch Neurol 64:169–176PubMedCrossRefGoogle Scholar
  76. 76.
    Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743–747PubMedCrossRefGoogle Scholar
  77. 77.
    Sullivan H, The CAMMS223 Study Group, ITP Following Treatment of Multiple Sclerosis Patients with Alemtuzumab in CAMMS223: Case Reports and Risk Management Plan Implementation. Neurology (Suppl 1):A206Google Scholar
  78. 78.
    Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, Young C, Moseley IF, MacManus DG, Donoghue S, Miller DH (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53:466–472PubMedGoogle Scholar
  79. 79.
    Tysabri (natalizumab) Information center. Form 8-K regarding other events; 31 July 2008. www.biogenidec.comGoogle Scholar
  80. 80.
    Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368PubMedCrossRefGoogle Scholar
  81. 81.
    Vermersch P, Zéphir H (2007) Immunosuppression with monoclonal antibodies in multiple sclerosis. Rev Neurol (Paris) 163:682–687PubMedCrossRefGoogle Scholar
  82. 82.
    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338:161–165PubMedCrossRefGoogle Scholar
  83. 83.
    Waldmann TA (2007) Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27:1–18PubMedCrossRefGoogle Scholar
  84. 84.
    Wingerchuk DM, Weinshenker BG (2005) Neuromyelitis Optica. Curr Treat Options Neurol 7:173–182PubMedCrossRefGoogle Scholar
  85. 85.
    Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, Stuve O, Monson N, Racke MK, Jacobsen S (2008) Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. Plos One 3:e208Google Scholar
  86. 86.
    Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2008

Authors and Affiliations

  • P. S. Rommer
    • 1
    Email author
  • O. Stüve
    • 2
  • R. Goertsches
    • 1
  • E. Mix
    • 1
  • U. K. Zettl
    • 1
  1. 1.Dept. of NeurologyUniversity of RostockRostockGermany
  2. 2.Dept. of NeurologyThe University of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations